RxDoctor Payments Data

Prashanth Rao, MD

Cardiovascular Disease · Lanham, MDNPI 1841462694

Payments from drug & device makers

$3,597in general payments, 2019–2025

Across 161 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$529
  • E.r. Squibb & Sons, L.L.C.$448
  • Novartis$415
  • Novo Nordisk$294
  • Pfizer$251
  • AstraZeneca$225
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,49797%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,597 in reported general payments places this provider in the 60th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$1,293,359
Medicare patients
1,344
Services billed
8,724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban129$147,508
EntrestoSacubitril/Valsartan61$72,517
FarxigaDapagliflozin Propanediol52$37,230
XareltoRivaroxaban25$32,214
Ezetimibe151$3,736
Carvedilol287$2,858
Atorvastatin Calcium240$2,712
Rosuvastatin Calcium81$1,953
Hydralazine Hcl99$1,924
Amlodipine Besylate208$1,401
Icosapent Ethyl14$1,333
Metoprolol Succinate87$1,196
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine12$833
Losartan Potassium60$638
ClopidogrelClopidogrel Bisulfate59$550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$251$147,508129 claims
NovartisEntresto$415$72,51761 claims
AstraZenecaFarxiga$225$37,23052 claims
Johnson & JohnsonXarelto$132$32,21425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Lanham

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →